Protalix Biotherapeutics (PLX) Announces Earnings Results, Misses Estimates By $0.06 EPS

Protalix Biotherapeutics (NYSEAMERICAN:PLX) announced its quarterly earnings data on Wednesday. The company reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.06), RTT News reports. The company had revenue of $0.66 million during the quarter, compared to analysts’ expectations of $8.00 million. During the same quarter in the previous year, the company earned ($0.09) earnings per share.

Protalix Biotherapeutics stock remained flat at $$0.46 during trading hours on Thursday. The company’s stock had a trading volume of 194,548 shares, compared to its average volume of 731,103. Protalix Biotherapeutics has a 12 month low of $0.38 and a 12 month high of $0.83.

A hedge fund recently raised its stake in Protalix Biotherapeutics stock. Renaissance Technologies LLC grew its stake in Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) by 13.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,614,700 shares of the company’s stock after acquiring an additional 305,200 shares during the quarter. Renaissance Technologies LLC owned about 1.80% of Protalix Biotherapeutics worth $1,124,000 at the end of the most recent quarter.

Several analysts have weighed in on PLX shares. HC Wainwright set a $4.00 target price on Protalix Biotherapeutics and gave the company a “buy” rating in a report on Monday, August 13th. Zacks Investment Research raised Protalix Biotherapeutics from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a report on Tuesday, July 31st.

ILLEGAL ACTIVITY WARNING: This story was originally published by WKRB News and is owned by of WKRB News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at

About Protalix Biotherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.

Further Reading: Discover Your Risk Tolerance

Earnings History for Protalix Biotherapeutics (NYSEAMERICAN:PLX)

Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with's FREE daily email newsletter.

Leave a Reply